Updated data from DeFianCe study continue to demonstrate statistically significant improvements in PFS among the DKK1-high, VEGF-naïve and liver metastasis subgroups Board of Directors has initiated process to explore strategic alternatives to maximize shareholder valueCAMBRIDGE, Mass., June 23, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported updated results from Part B of the DeFianCe study ( ...

Core Viewpoint - iTeos Therapeutics, Inc. intends to wind down its operations as part of a strategic review aimed at maximizing shareholder value through potential asset sales and leveraging its cash balance [2][3]. Group 1: Company Operations - The Board of Directors has decided to cease clinical and operational activities following a comprehensive assessment of the company's development pipeline and financial position [3]. - The company is exploring potential asset sales, including EOS-984, EOS-215, and a preclinical obesity program targeting ENT1, to deliver near-term value to shareholders [2][3]. Group 2: Company Background - iTeos Therapeutics is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapeutics, leveraging its expertise in tumor immunology [4].